Clinical Cooperation Unit Neuropathology (G380), German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
Acta Neuropathol. 2018 Aug;136(2):303-313. doi: 10.1007/s00401-018-1840-0. Epub 2018 Mar 22.
Medulloblastoma with extensive nodularity (MBEN) is a rare histological variant of medulloblastoma (MB). These tumors are usually occurring in the first 3 years of life and are associated with good prognosis. Molecular analyses of MBEN, mostly limited to single cases or small series, have shown that they always classify as sonic hedgehog (SHH)-driven MB. Here, we have analyzed 25 MBEN through genome-wide DNA methylation, copy-number profiling and targeted next-generation sequencing. Results of these analyses were compared with molecular profiles of other SHH MB histological variants. As expected, the vast majority of MBEN (23/25) disclosed SHH-associated epigenetic signatures and mutational landscapes but, surprisingly, two MBEN were classified as Group 3/4 MB. Most MBEN classified as SHH MB displayed SHH-related and mutually exclusive mutations in either SUFU, or PTCH1, or SMO at similar frequencies. However, only SUFU mutations were also identified in the germ-line. Most of SUFU-associated MBEN eventually recurred but patients were treated successfully with second-line high-dose chemotherapy. Altogether, our data show that risk stratification even for well-recognizable histologies such as MBEN cannot rely on histology alone but should include additional molecular analyses such as methylation profiling and DNA sequencing. For all patients with "MBEN" histology, we recommend sequencing SUFU and PTCH1 in the tumor as well as in the germ-line for further clinical stratification and choice of the optimal treatment strategy upfront.
广泛结节性髓母细胞瘤(MBEN)是髓母细胞瘤(MB)的一种罕见组织学变体。这些肿瘤通常发生在生命的头 3 年,并且与良好的预后相关。MBEN 的分子分析,主要限于单个病例或小系列,表明它们总是归类为 sonic hedgehog(SHH)驱动的 MB。在这里,我们通过全基因组 DNA 甲基化、拷贝数谱分析和靶向下一代测序分析了 25 例 MBEN。这些分析的结果与其他 SHH MB 组织学变体的分子谱进行了比较。不出所料,绝大多数 MBEN(23/25)显示出与 SHH 相关的表观遗传特征和突变景观,但令人惊讶的是,有两个 MBEN 被归类为 3/4 组 MB。大多数被归类为 SHH MB 的 MBEN 显示出 SHH 相关的和相互排斥的突变,要么在 SUFU 中,要么在 PTCH1 中,要么在 SMO 中,频率相似。然而,只有 SUFU 突变也在种系中被识别。大多数与 SUFU 相关的 MBEN 最终复发,但患者成功地接受了二线高剂量化疗治疗。总的来说,我们的数据表明,风险分层,即使是对于可识别的组织学,如 MBEN,不能仅依赖于组织学,而应包括其他分子分析,如甲基化谱分析和 DNA 测序。对于所有具有“MBEN”组织学的患者,我们建议在肿瘤和种系中对 SUFU 和 PTCH1 进行测序,以进行进一步的临床分层,并选择最佳的治疗策略。